Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2002
12/27/2002WO2002004623A3 ANTISENSE COMPOSITIONS TARGETED TO β1 ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE
12/27/2002WO2002004514A8 Compositions and methods for the therapy and diagnosis of lung cancer
12/27/2002WO2002000877A3 Antisense oligonucleotides to inhibit angiogenesis and/or metastasis
12/27/2002WO2001097829A3 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
12/27/2002WO2001096390A3 Compositions and methods for the therapy and diagnosis of colon cancer
12/27/2002WO2001094587A3 Extracellular messengers
12/27/2002WO2001091699A3 Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways
12/27/2002WO2001087935A9 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
12/27/2002WO2001078706A9 Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
12/27/2002WO2001075119A9 21509 and 33770, novel human dehydrogenase family members and uses thereof
12/27/2002WO2001074903A9 Cd20/ige-receptor like molecules and uses thereof
12/27/2002WO2001058947A9 Lipophilin complexes for use in cancer diagnosis and therapy
12/27/2002WO2001052904A9 Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides
12/27/2002WO2001034631A3 PEPTIDE ANALOGS AND MIMETICS SUITABLE FOR IN VIVO USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL PROTEIN FOLDING INTO AMYLOID, AMYLOID-LIKE DEPOSITS OR β-SHEET RICH PATHOLOGICAL PRECURSOR THEREOF
12/27/2002WO2001021574A9 Systems and methods for opening obstructed biological conduits
12/27/2002WO2001011028A9 Glucuronoxylomannan (gxm)-o-acetylhydrolase of cryptococcus neoformans and uses thereof
12/27/2002WO2000052184A9 Anti-neoplastic compositions and uses thereof
12/27/2002CA2753372A1 Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
12/27/2002CA2465075A1 Hdac9 polypeptides and polynucleotides and uses thereof
12/27/2002CA2455387A1 Fce fusion proteins for treatment of allergy and asthma
12/27/2002CA2455254A1 Moraxella (branhamella) catarrhalis antigens
12/27/2002CA2451874A1 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells
12/27/2002CA2451058A1 Novel nucleic acids, polypeptides, methods of making, and uses thereof
12/27/2002CA2450845A1 Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state
12/27/2002CA2450793A1 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
12/27/2002CA2450732A1 Stabilized proteins with engineered disulfide bonds
12/27/2002CA2450678A1 Novel polypeptide and use thereof
12/27/2002CA2450666A1 Diagnosing tumorigenicity and determining resistance to anticancer therapy
12/27/2002CA2450658A1 Essential and important genes of pseudomonas aeruginosa and the use thereof to design or identify antibacterial agents
12/27/2002CA2450590A1 Methods and compositions for inhibiting, preventing or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
12/27/2002CA2450288A1 Novel human transporter proteins and polynucleotides encoding the same
12/27/2002CA2450127A1 Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, bgs-8, expressed highly in immune tissue
12/27/2002CA2450067A1 Proteins associated with cell growth, differentiation, and death
12/27/2002CA2449977A1 Human growth hormone antagonists
12/27/2002CA2449950A1 Agents for treating diseases caused by nonsense mutation
12/27/2002CA2449910A1 Use of glycoprotein for the treatment and re-epithelialisation of wounds
12/27/2002CA2449909A1 Male contraceptives
12/27/2002CA2449898A1 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
12/27/2002CA2449288A1 Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
12/27/2002CA2448971A1 Chimeric flavivirus vectors
12/27/2002CA2448506A1 Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans
12/27/2002CA2446285A1 Fibroblast growth factor and nucleic acid encoding same
12/27/2002CA2445261A1 Human tachykinin-related splice variants and compositions thereof
12/27/2002CA2444876A1 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists
12/27/2002CA2441832A1 Human secreted proteins
12/27/2002CA2441702A1 Human secreted proteins
12/27/2002CA2427928A1 The use of bacterial phage associated lytic enzymes to prevent food poisoning
12/26/2002US20020198372 Methods for purifying nucleic acids
12/26/2002US20020198366 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/26/2002US20020198363 Generation of antithrombic protein; obtain nucleotide sequences coding antithrombic protein, transform microorganism, express nucleotide sequences, recover protein
12/26/2002US20020198361 Diagnosis and treatment of osteoporosis; obtain humans, administer modulator, monitor response to modulator
12/26/2002US20020198360 Structural models for cytoplasmic domains of transmembrane receptors
12/26/2002US20020198315 Useful in the formulation of extended release pharmaceutical compositions
12/26/2002US20020198263 Preventing or treating deficiency by administering l-carnitine or a salt
12/26/2002US20020198242 Administering to an animal an effective dose of atleast an enzyme Dipeptidyl Peptidase (DP IV) enzyme activity effector to increase the capacity of insulin producing cells
12/26/2002US20020198211 cDNA for human methylenetetrahydrofolate reductase and uses thereof
12/26/2002US20020198187 Method of treating sexual disturbances
12/26/2002US20020198186 Dissolving the peptide in acetic acid to form a solution, mixing with water, and lyophilizing; treating female infertility and for gonad protection
12/26/2002US20020198173 Viricides for treating HIV and hepatitis virus
12/26/2002US20020198167 Transfecting an ovarian tumor cell with a vector encoding human UDP-glucuronosyltransferase 2B7, wherein constant or temporal expression of UDP-glucuronosyltransferase 2B7 in that cell results growth arrest of tumor cells
12/26/2002US20020198166 Method for treatment of cancer and infectious diseases and compositions useful in same
12/26/2002US20020198164 A toxin gene is expressed under the transcriptional control of a human prostate-specific transcriptional regulatory sequence
12/26/2002US20020198161 Sulphur-containing antioxidant is selected from the group consisting of N- acetylcysteine, 2,3-dimercaptopropanol, L-2-oxo-4-thiazolidinecarboxylate and lipoic acid, useful for cancer treatment
12/26/2002US20020198160 Compositions and methods for enhancing the bioavailability of pharmaceutical agents
12/26/2002US20020198156 Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor
12/26/2002US20020198155 Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders
12/26/2002US20020198154 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
12/26/2002US20020198153 Administering to an individual for tumor treatment a chemotherapeutically effective amount of antitumor agent carboplatin, and erythropoietin a hematocrit elevator which is administered befor or concurrently with antitumor agent
12/26/2002US20020198151 Intracellular inhibitors of Gq protein signaling
12/26/2002US20020198150 Administering to a patient who has suffered central nervous system injury, a colony stimulating growth factor in a dosage sufficient to increase the number of bone-marrow-derived stem cells in the circulation of the patient
12/26/2002US20020198149 Polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides; native membrane-bound proteins; PRO polypeptides
12/26/2002US20020198148 Polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides; native membrane-bound proteins; PRO polypeptides
12/26/2002US20020198147 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/26/2002US20020198146 Method for the synthesis of peptide salts, their use and the pharmaceutical preparations, containing peptide salts
12/26/2002US20020198145 Have long lasting anesthetic activity and are particularly useful for spinal anesthesia
12/26/2002US20020198144 MHC molecule that contains a peptide-binding groove, and a presenting peptide covalently linked to the MHC molecule, the fusion complex being capable of modulating the activity of a T cell.
12/26/2002US20020198143 B7-like polynucleotides, polypeptides, and antibodies
12/26/2002US20020198142 Integrin inhibitors, for the treatment of disorders caused by implants, defects, inflammations and of osteolytic disorders such as osteoporosis, thrombosis, cardiac infarct and arteriosclerosis
12/26/2002US20020198141 Molecular conjugates for use in treatment of cancer
12/26/2002US20020198140 Administering zinc-free acylated insulin or analog via a pulmonary route; especially in powder form
12/26/2002US20020198139 Associated with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) by administering HSP70 protein.
12/26/2002US20020198138 Combination therapy for the treatment of inflammatory and respiratory diseases
12/26/2002US20020198136 Treating vaginismus, dyspareunia, interstitial cystitis, vulvodynia, vulvar vestibulitis, nonspecific urethritis, female sexual arousal orgasmic disorders or increasing vaginal lubrication, etc.
12/26/2002US20020197737 Novel methods for testing inhibitors of paired helical filaments and uses for treatment of alzheimer's disease
12/26/2002US20020197712 Polypeptide for use as tools in analyzing enzymatic gene expression
12/26/2002US20020197706 Mutant membrane protein for use in the treatment of defects in signal tranduction
12/26/2002US20020197702 Nucleotide sequences coding polypeptide for use in the treatment of cancer, viral and bacterial infections and autoimmune diseases
12/26/2002US20020197700 Receptor of the EDb-fibronectin domains
12/26/2002US20020197699 Polypeptide for use in the treatment of arteriolosclerosis
12/26/2002US20020197684 Ribozymes; for use as amplification tools in genetic engineering
12/26/2002US20020197681 Identification and uses of a hyaluronan receptor for endocytosis
12/26/2002US20020197680 54420, a novel human calcium channel
12/26/2002US20020197675 Glial nerovus system modulator for use in the treatment of nervous system disorders and spine damage
12/26/2002US20020197674 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/26/2002US20020197671 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/26/2002US20020197670 Membrane associated progesterone receptor
12/26/2002US20020197669 Nucleotide sequences coding polypeptide for use in the treatment and prevention of cancer
12/26/2002US20020197667 Polypeptide for use in the treatment of thrombosis and sepsis
12/26/2002US20020197666 Human chordin-related proteins and polynucleotides encoding them
12/26/2002US20020197660 Novel molecules of the PYRIN domain protein family and uses thereof
1 ... 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 ... 3163